Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

14.10 EUR

-0.70 %

5,597 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-0.70 %
-4.73 %
+11.02 %
+38.24 %
+78.48 %
+114.94 %
+223.39 %
+169.59 %
-97.67 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
101.71M EUR
Turnover
50.15K EUR
P/E (adj.) (25e)
24.96
EV/EBIT (adj.) (25e)
24.28
P/B (25e)
12.9
EV/S (25e)
6.58
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.50 EUR
Updated
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.08.2025

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Added nexstim last week. Although no deals have been announced in December, I trust the company’s long-term story. The company is growing strongly this year and will also become solidly profitable at the EBIT level. In fact, the key figures will be among the elite of the Helsinki...
yesterday
by Tomi Lindell
36
I wonder if this Danish deal has been announced at all? The advent calendar might be seriously off. The only trade announcement this could match was from July, and I don’t believe in such a long delivery time. linkedin.com Such a great milestone and so impressed by the team at Privathospit...
yesterday
by Kyhnykeisari
27
I just saw the same thing myself. I’ve come to the conclusion that no deals will be announced for December. Otherwise, it would be too easy to calculate, for example, Brainlab’s share of sales from them. (If that information was meant to be kept private). And if only one or two of...
22 hours ago
by Hannu
9
Reaching Inderes’ estimate requires very brisk sales and also deliveries for this year, or alternatively, it requires that Brainlab has sold and Sinaptica has ordered devices that have not been announced. It would be nice to get clarified information from Nexstim regarding these ...
yesterday
by Jatast
9
It’s a bit nerve-wracking what will come out of it when nothing is announced. I’d like to add more, but what if… It’s already one of the biggest in the portfolio. On the other hand, the future looks promising anyway. A considerable rise is expected if sales come in even as expected...
21 hours ago
by QRB Strong buy
8
The guidance is broad and has no upper limit in this case. There’s no point in announcing it if it’s within the guidelines. Besides, if it’s difficult to give an exact precise estimate, I don’t see any point in elaborating on it at this point in the year. Talking won’t turn black...
yesterday
by Hannu
6
I don’t personally recall such an announcement from Karvinen, but I find this reasoning more sensible than the sudden cessation of store announcements. Customs issues also certainly boosted trading to some extent, even though the CEO said it had little, if any, weight. Still valid...
14 hours ago
by Tee
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.